Taxotere Lawsuit Update 2022 – Judge Allows New Trial to Go forward in Class Action Lawsuit.
Taxotere lawsuit update 2022. One of the fastest growing cases in the pharmaceutical space concerns the cancer drug Taxotere.
Taxotere Vision Damage Lawsuits
Taxotere lawsuit update 2022. Taxotere is a breast cancer chemotherapy drug which initially hit the news when women started experiencing permanent hair loss from the drug. But more recently, there have been a flood of product liability cases due to women alleging Taxotere caused permanent vision damage.
There is already an MDL with approximately 30,000 Taxotere hair loss related lawsuits. This new vision damage litigation is separate. As a result, these lawsuits will be consolidated into its own MDL.
Use of Taxotere as a Cancer Treatment
Taxotere lawsuit update 2022. Taxotere, also known as docetaxel, was approved by the U.S. Food & Drug Administration to treat a variety of cancers, including breast cancer, prostate cancer, some lung cancers and head and neck cancer. The drug is manufactured by Sanofi-Aventis and is often used in conjunction with other drugs and therapies.
Like many chemotherapy drugs, various side effects were common with Taxotere including low blood cell count, nausea and vomiting and hair loss. However, marketing for the drug focused on it being safer and more effective than other types of treatments.
Taxotere and Permanent Hair Loss
Hair loss is a noted side effect of many types of chemotherapy treatments, but most patients regrow their hair back within six months after completion.
Some women who used Taxotere as part of breast cancer treatment began experiencing permanent hair loss (alopecia) upon completion of their treatments, even though Sanofi-Aventis didn’t initially warn about this as a potential side effect.
The drug was introduced on the market in the mid-1990’s, and studies from as far back as the late 1990’s showed links between permanent hair loss and the use of Taxotere, indicating 10% or more of patients could experience such side effects. Sanofi-Aventis did not include warnings about such problems until 2015.
2022 Update: Taxotere lawsuit allowed to go forward by judge.
Women devastated by the permanent hair loss caused by Taxotere began filing claims against Sanofi-Aventis accusing the manufacturer of false claims and negligence in failing to adequately warn about such side effects.
In late 2016, an MDL was established in the U.S. District Court in Eastern Louisiana with future trials being heard by Judge Kurt D. Engelhardt. Within a year, almost 2,000 claims were filed within the MDL and the case has continued to grow exponentially, with around 12,000 claims pending by the beginning of 2019.
Taxotere lawsuit update 2022. While there is no news of any settlements yet in these cases, a series of bellwether trials are scheduled to take place beginning in 2019. It remains to be seen if Sanofi-Aventis will attempt negotiations to arrive at some global settlement agreement, given the rapid rise in claims against them involving Taxotere.
When Taxotere Claims Settle, Balanced Bridge Can Help With Post-Settlement Advances
Once plaintiffs begin to receive settlements in their Taxotere cases, Balanced Bridge would be in position to provide advances against those pending awards and also against pending attorney fees for claimants or attorneys who can’t afford to wait until distribution.
Balanced Bridge specializes in post-settlement funding solutions for both attorneys and plaintiffs. To learn more about how our legal funding solutions help with delayed settlements, you can browse through our website or call us at 267-457-4540 to speak directly with a legal funding specialist. Balanced Bridge is happy to answer any questions you may have and discuss the funding process in more detail.